Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | AGER | Q15109 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313863 | 0.82 | ESR1 (0.58) | F2RL1CASP6AGERSYK | |
| SCHEMBL1353526 | 0.82 | METAP2 (0.47) | F2RL1METAP2METAP1CASP6SYK | |
| SCHEMBL10151023 | 0.77 | MPL (0.50) | METAP2METAP1CASP6NPC1RAB9A | |
| SCHEMBL6313842 | 0.76 | SYK (0.43) | F2RL1METAP1NPC1RAB9AHCRTR1 | |
| SCHEMBL6511392 | 0.76 | SYK (0.39) | F2RL1METAP2METAP1CASP6KMO | |
| SCHEMBL19584793 | 0.75 | METAP2 (0.50) | F2RL1METAP2METAP1CASP6MEN1 | |
| SCHEMBL28154582 | 0.75 | METAP1 (0.41) | F2RL1METAP2METAP1CASP6NPC1 | |
| SCHEMBL23249827 | 0.74 | F2RL1 (0.47) | F2RL1METAP2METAP1CASP6MEN1 | |
| SCHEMBL14754343 | 0.73 | METAP1 (0.45) | F2RL1METAP1CASP6 | |
| SCHEMBL3766113 | 0.73 | MAOA (0.51) | NPC1RAB9AMEN1KMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1226555-A | Antifungal agent, and preparation method and intermediate thereof | — | 1999-08-25 | — | — | CN | claimed |
| EP-0667346-A2 | Azole antifungal agents, process for the preparation there of and intermediates | Eisai Co., Ltd. (JP) | 1995-08-16 | — | — | EP | claimed |
| JP-7223950-A | — | — | None | — | — | JP | disclosed |
| CN-109293652-A | A kind of substituted thiazole and application thereof | 四川科伦博泰生物医药股份有限公司 | 2019-02-01 | — | — | CN | disclosed |
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2007062222-A2 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1394162-A1 | Intermediates of azole antifungal agents and processes for the preparation thereof | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1394142-A1 | Carboxylic acid intermediates of antifungal agents and processes for the preparation thereof | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1231210-A2 | Azole antifungal agents, processes for the preparation thereof, and intermediates | Eisai Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
| CN-1226555-A | Antifungal agent, and preparation method and intermediate thereof | — | 1999-08-25 | — | — | CN | disclosed |
| US-5792781-A | EFFECTIVE AGAINST DERMATOMYCOSIS/VISCEROMYCOSIS CAUSED BY FUNGI, I.E., CANDIDA ALBICANS | EISAI CO., LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5789429-A | FUNGICIDE | EISAI CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| US-5648372-A | TRIAZOLES | EISAI CO., LTD. (JP) | 1997-07-15 | — | — | US | disclosed |
| JP-H07223950-A | ANTIFUNGAL AGENT AND ITS PRODUCTION | EISAI CO LTD | 1995-08-22 | — | — | JP | disclosed |
| EP-0667346-A2 | Azole antifungal agents, process for the preparation there of and intermediates | Eisai Co., Ltd. (JP) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | F2RL1 2820/4885METAP2 4373/4885METAP1 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.